Alexion Pharmaceuticals Inc. Reports First Quarter 2012 Results

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the three months ended March 31, 2012. The Company reported net product sales of Soliris® (eculizumab) of $244.7 million, an increase of 47 percent from the same period in 2011. Revenue performance for the quarter reflects steady additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) in Alexion’s core territories of the US, Western Europe, Japan and in other countries, augmented by a steady increase in new patients with atypical Hemolytic Uremic Syndrome (aHUS).